

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1                   1.       (currently amended) A method for inhibiting ~~and preventing~~ a malignant  
2 cell phenotype, said method comprising: administering to cells a low dose of a nitric oxide  
3 mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic  
4 that produces vasodilation.

1                   2.       (original) The method of claim 1 wherein the cells are in a subject at risk  
2 for or suffering from a malignant cell phenotype.

1                   3.       (original) The method of claim 1 or 2 wherein administration of the nitric  
2 oxide mimetic inhibits metastases and development of resistance to antimalignant therapeutic  
3 modalities in the cells.

1                   4.       (original) The method of claim 1 or 2 wherein administration of the nitric  
2 oxide mimetic inhibits development of a more aggressive malignant cell phenotype in the cells  
3 upon administration of an anti-VEGF agent.

1                   5.       (original) The method of claim 1 or 2 wherein administration of the nitric  
2 oxide mimetic inhibits development of a malignant cell phenotype in cells exposed to factors  
3 which lower cellular nitric oxide mimetic activity.

1                   6-7.   (canceled)

1                   8.       (currently amended) A method for increasing efficacy of an antimalignant  
2 therapeutic modality against cancer cells, said method comprising: administering to ~~the~~ said cells  
3 a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose  
4 of said nitric oxide mimetic that produces vasodilation.

1                   **9-12.** (canceled)

1                   **13.** (currently amended) A method for inhibiting ~~and preventing~~ a malignant  
2 cell phenotype in an animal, said method comprising: administering to ~~an~~ said animal in need  
3 thereof a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than  
4 a dose of said nitric oxide mimetic that produces vasodilation.

1                   **14-15.** (canceled)

1                   **16.** (original) The method of claim **13** wherein administration of the nitric  
2 oxide mimetic inhibits tumor metastases and development of resistance to antimalignant  
3 therapeutic modalities in cells in the animal.

1                   **17.** (original) The method of claim **13** wherein administration of the nitric  
2 oxide mimetic inhibits development of a more aggressive malignant cell phenotype in cells in the  
3 animal upon administration of an anti-VEGF agent to the animal.

1                   **18.** (original) The method of claim **13** wherein administration of the nitric  
2 oxide mimetic inhibits development of a malignant cell phenotype in animals exposed to factors  
3 which lower cellular nitric oxide mimetic activity.

1                   **19.** (currently amended) A method of treating cancer in a subject, said method  
2 comprising administering to ~~a~~ said subject in need thereof a low dose of a nitric oxide mimetic,  
3 wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that  
4 produces vasodilation.

1                   **20-21.** (canceled)

1                   **22.** (original) The method of claim **19** wherein the cancer is prostate cancer.

1                   **23-29.** (canceled)

1                   **30-32.** (canceled)

1                   **33.**     (new) A method for inhibiting a malignant cell phenotype, said method  
2 comprising administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is  
3 between about  $10^{-14}$  M to about  $10^{-6}$  M of said nitric oxide mimetic.

1                   **34.**     (new) The method of claim 33, wherein said low dose is between about  
2  $10^{-14}$  M to about  $10^{-10}$  M of said nitric oxide mimetic.

1                   **35.**     (new) A method for increasing efficacy of an antimalignant therapeutic  
2 modality against cancer cells, said method comprising administering to said cells a low dose of a  
3 nitric oxide mimetic, wherein said low dose is between about  $10^{-14}$  M to about  $10^{-6}$  M of said  
4 nitric oxide mimetic.

1                   **36.**     (new) The method of claim 35, wherein said low dose is between about  
2  $10^{-14}$  M to about  $10^{-10}$  M of said nitric oxide mimetic.

1                   **37.**     (new) A method for inhibiting a malignant cell phenotype in an animal,  
2 said method comprising administering to said animal in need thereof a low dose of a nitric oxide  
3 mimetic, wherein said low dose is between about  $10^{-14}$  M to about  $10^{-6}$  M of said nitric oxide  
4 mimetic.

1                   **38.**     (new) The method of claim 37, wherein said low dose is between about  
2  $10^{-14}$  M to about  $10^{-10}$  M of said nitric oxide mimetic.

1                   **39.**     (new) A method for treating cancer in a subject, said method comprising  
2 administering to said subject in need thereof a low dose of a nitric oxide mimetic, wherein said  
3 low dose is between about  $10^{-14}$  M to about  $10^{-6}$  M of said nitric oxide mimetic.

1                   **40.**     (new) The method of claim 39, wherein said low dose is between about  
2  $10^{-14}$  M to about  $10^{-10}$  M of said nitric oxide mimetic.